行情

TBPH

TBPH

Theravance生物制药
NASDAQ

实时行情|Nasdaq Last Sale

23.11
+0.05
+0.22%
盘后: 23.11 0 0.00% 17:32 03/31 EDT
开盘
22.98
昨收
23.06
最高
23.36
最低
22.13
成交量
28.70万
成交额
--
52周最高
31.54
52周最低
15.18
市值
14.56亿
市盈率(TTM)
-5.4325
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测TBPH价格均价为32.29,最高价位40.00,最低价为20.00。

EPS

TBPH 新闻

更多
  • 美国2万亿刺激计划流向何处?私募股权公司或成最大输家
  • 新浪美股 · 59分钟前
  • 消息称施乐已放弃340亿美元收购惠普要约
  • 新浪科技 · 59分钟前
  • "美国徐翔"Steven Cohen呼吁保持谨慎:"地震过后当心余震"
  • 新浪美股 · 1小时前
  • 国际货币基金组织:对今年全球经济前景非常担忧
  • 央视 · 1小时前

所属板块

制药
-0.13%
制药与医学研究
-0.17%

热门股票

代码
价格
涨跌幅

TBPH 简况

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
展开

微牛提供Theravance Biopharma Inc(NASDAQ-TBPH)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的TBPH股票新闻,以帮助您做出投资决策。